Division of Hematology/Oncology, Department of Medicine, Hillman Cancer Center, University of Pittsburgh.
Division of Gynecologic Oncology, Department of Obstetrics, Gynecology, and Reproductive Sciences, Magee-Womens' Hospital, University of Pittsburgh Medical Center.
J Vis Exp. 2021 Mar 23(169). doi: 10.3791/62382.
Ovarian cancer is characterized by early, diffuse metastasis with 70% of women having metastatic disease at the time of diagnosis. While elegant transgenic mouse models of ovarian cancer exist, these mice are expensive and take a long time to develop tumors. Intraperitoneal injection xenograft models lack human stroma and do not accurately model ovarian cancer metastasis. Even patient derived xenografts (PDX) do not fully recapitulate the human stromal microenvironment as serial PDX passages demonstrate significant loss of human stroma. The ability to easily model human ovarian cancer within a physiologically relevant stromal microenvironment is an unmet need. Here, the protocol presents an orthotopic ovarian cancer mouse model using human ovarian cancer cells combined with patient-derived carcinoma-associated mesenchymal stem cells (CA-MSCs). CA-MSCs are stromal progenitor cells, which drive the formation of the stromal microenvironment and support ovarian cancer growth and metastasis. This model develops early and diffuses metastasis mimicking clinical presentation. In this model, luciferase expressing ovarian cancer cells are mixed in a 1:1 ratio with CA-MSCs and injected into the ovarian bursa of NSG mice. Tumor growth and metastasis are followed serially over time using bioluminescence imaging. The resulting tumors grow aggressively and form abdominal metastases by 14 days post injection. Mice experienced significant decreases in body weight as a marker of systemic illness and increased disease burden. By day 30 post injection, mice met endpoint criteria of >10% body weight loss and necropsy confirmed intra-abdominal metastasis in 100% of mice and 60%-80% lung and parenchymal liver metastasis. Collectively, orthotopic engraftment of ovarian cancer cells and stroma cells generates tumors that closely mimic the early and diffuse metastatic behavior of human ovarian cancer. Furthermore, this model provides a tool to study the role of ovarian cancer cell: stroma cell interactions in metastatic progression.
卵巢癌的特征是早期广泛转移,70%的女性在诊断时已发生转移。虽然存在优雅的卵巢癌转基因小鼠模型,但这些小鼠昂贵且需要很长时间才能形成肿瘤。腹腔内注射异种移植模型缺乏人类基质,不能准确模拟卵巢癌转移。即使是患者来源的异种移植(PDX)也不能完全再现人类基质微环境,因为连续的 PDX 传代会导致明显的人类基质丢失。在生理相关的基质微环境中轻松模拟人类卵巢癌的能力是未满足的需求。在这里,该方案介绍了一种使用人类卵巢癌细胞结合患者来源的癌相关间充质干细胞(CA-MSCs)的卵巢癌原位小鼠模型。CA-MSCs 是基质祖细胞,可驱动基质微环境的形成,并支持卵巢癌细胞的生长和转移。该模型早期发展并扩散转移,模拟临床表现。在该模型中,将表达荧光素酶的卵巢癌细胞与 CA-MSCs 以 1:1 的比例混合,并注入 NSG 小鼠的卵巢囊。使用生物发光成像技术,随时间连续跟踪肿瘤生长和转移。生成的肿瘤生长迅速,在注射后 14 天形成腹部转移。小鼠的体重显著下降,作为全身性疾病的标志物,并增加了疾病负担。在注射后 30 天,小鼠达到了体重减轻超过 10%的终点标准,尸检证实 100%的小鼠和 60%-80%的肺和实质肝转移有腹腔内转移。总之,卵巢癌细胞和基质细胞的原位移植会产生肿瘤,这些肿瘤非常类似于人类卵巢癌的早期和广泛转移行为。此外,该模型提供了一种工具来研究卵巢癌细胞与基质细胞相互作用在转移进展中的作用。